Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 01:00 save search
Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: -0.38%
H: 0.14%
C: -0.14%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 2.0%
H: 2.28%
C: 1.63%
ADMA 4 | $6.21 2.82% 2.74% 3M
|
Health Technology
|
| O: 0.19%
H: 2.5%
C: 1.35%
report reach global set therapy growth market
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Celebrating National Physical Therapy Month
Published: 2023-10-26 (Crawled : 01:00) - penumbrainc.com
PEN F | $201.84 -3.28% 0.0% 330K
|
Health Technology
|
| O: -0.33%
H: 0.51%
C: -2.48%
therapy
Global Gene Therapy Market to Grow by $4.61 Billion During 2023-2027
Published: 2023-03-14 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 1.01%
H: 0.43%
C: 0.29%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: 0.31%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.01%
H: 7.6%
C: 7.6%
GBIO | $2.775 -6.88% -7.39% 200K
|
Health Technology
|
| O: 3.79%
H: 2.61%
C: -1.57%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 1.4%
H: 1.39%
C: 0.07%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -1.23%
ADAP | $0.8984 -8.98% -9.86% 3.3M
|
Health Technology
|
| O: 0.9%
H: 4.46%
C: 2.68%
ABEO | $7.55 -4.79% -5.03% 250K
|
Health Technology
|
| O: 2.79%
H: 8.53%
C: 0.78%
global therapy market
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-03-07 (Crawled : 01:00) - prnewswire.com
BMRN S | $90.08 -0.43% -0.43% 940K
|
Health Technology
|
| O: -0.88%
H: 2.17%
C: -0.05%
fda review therapy update
Global CAR-T Cell Therapy Market Report 2023: Switchable CARs, Suicide Genes & Transient Transfection to Reshape Sector Moving Forward
Published: 2023-01-06 (Crawled : 01:00) - prnewswire.com
ACLX | $54.5 1.77% 1.74% 600K
|
|
| O: 0.95%
H: 2.51%
C: -0.77%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 3.99%
H: 19.78%
C: 17.57%
APDN | $0.3461 3.93% 3.79% 130K
|
Commercial Services
|
| O: -3.03%
H: 6.25%
C: 3.12%
ANIX | News | $3.09 1.31% 1.29% 59K
|
Health Technology
|
| O: 2.43%
H: 1.9%
C: -2.85%
global report car-t therapy market
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.59%
H: 0.15%
C: -0.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.63%
H: 2.86%
C: 2.01%
ibi351 designation lung therapy cancer
SPECTRUM PARTNERS WITH OVATION TV TO SUPPORT RENO'S NOTE-ABLE MUSIC THERAPY SERVICES WITH $10,000 STAND FOR THE ARTS AWARD
Published: 2022-11-11 (Crawled : 01:00) - prnewswire.com
CHTR | $259.82 0.69% 0.69% 860K
|
Consumer Services
|
| O: 1.18%
H: 5.43%
C: 4.46%
award services therapy
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
Published: 2022-09-13 (Crawled : 01:00) - biospace.com/
RGBP | $0.5678 5.69% 2K
|
Manufacturing
|
| O: 4.05%
H: 15.58%
C: 10.39%
car-t therapy
Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy
Published: 2022-08-01 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.66%
H: 0.89%
C: -1.03%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.32%
H: 1.19%
C: -0.04%
treatment therapy study
Innovent and IASO Bio Present Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022
Published: 2022-06-13 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -3.12%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -3.69%
H: 0.0%
C: 0.0%
car-t therapy
SeaStar Medical Granted FDA Breakthrough Device Designation for a Novel Immunomodulatory Therapy for Acute Kidney Injury Patients
Published: 2022-05-03 (Crawled : 01:00) - biospace.com/
LMAO | $12.35 3.89%
|
|
| O: 0.1%
H: 0.0%
C: 0.0%
fda designation device kidney granted therapy
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
Published: 2022-03-24 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: -1.11%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: 0.0%
novartis treatment fda therapy cancer prostate cancer
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Published: 2022-03-23 (Crawled : 01:00) - globenewswire.com
SCPS | $0.1682
|
|
| O: 1.23%
H: 12.2%
C: 2.44%
therapy
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
Published: 2022-02-14 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: -0.94%
H: 0.21%
C: -0.69%
fda car-t drug drug designation cel orphan drug therapy grant t-cell designation
ImmunityBio Announces Promising Clinical Study Results For ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy
Published: 2022-02-01 (Crawled : 01:00) - nantkwest.com
IBRX | $4.92 -6.11% -6.5% 3.5M
|
Manufacturing
|
| O: 9.56%
H: 2.52%
C: 2.18%
therapy hiv
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
NEXI | $3.15 -11.94% 6.9K
|
|
| O: -4.85%
H: 0.0%
C: 0.0%
program leukemia cel therapy
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-01-04 (Crawled : 01:00) - biospace.com/
JAGX | $0.1772 7.46% 6.94% 68M
|
Health Technology
|
| O: 3.74%
H: 0.0%
C: 0.0%
treatment health diarrhea therapy crofelemer
629AB, Associate Director / Principal Scientist, Flow Cytometry Cell Therapy Analytics
Published: 2021-12-24 (Crawled : 01:00) - fatetherapeutics.com
FATE | $5.04 -4.36% -4.56% 2.3M
|
Health Technology
| Email alert
Add to watchlist
analytics cel therapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.